Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Feb;38(2):369–370. doi: 10.1128/aac.38.2.369

Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.

G A Pankuch 1, M R Jacobs 1, P C Appelbaum 1
PMCID: PMC284459  PMID: 8192468

Abstract

The susceptibilities of 123 clinically isolated strains of Xanthomonas maltophilia to six fluoroquinolones (clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin) were examined by microdilution MIC methodology. Clinafloxacin and PD 131628 were the most active compounds tested (MICs for 50% of the strains tested [MIC50s] of 0.5 and 1.0 microgram/ml and MIC90s of 2.0 and 4.0 micrograms/ml, respectively). PD 138312, PD 140248, ciprofloxacin, and ofloxacin were less active, with MIC50s ranging from 4.0 to 8.0 micrograms/ml and MIC90s of 16.0 micrograms/ml for all four compounds. Only clinafloxacin and PD 131628 were active against ciprofloxacin-resistant strains, with MIC50s of 0.5 and 1.0 microgram/ml and MIC90s of 2.0 and 4.0 micrograms/ml, respectively.

Full text

PDF
369

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barry A. L., Fass R. J., Anhalt J. P., Neu H. C., Thornsberry C., Tilton R. C., Painter B. G., Washington J. A., 2nd Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks. J Clin Microbiol. 1985 Jun;21(6):880–883. doi: 10.1128/jcm.21.6.880-883.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bonfiglio G., Livermore D. M. Effect of media composition on the susceptibility of Xanthomonas maltophilia to beta-lactam antibiotics. J Antimicrob Chemother. 1991 Dec;28(6):837–842. doi: 10.1093/jac/28.6.837. [DOI] [PubMed] [Google Scholar]
  3. Chow A. W., Wong J., Bartlett K. H. Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia. Antimicrob Agents Chemother. 1988 May;32(5):782–784. doi: 10.1128/aac.32.5.782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Domagala J. M., Heifetz C. L. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141–146. doi: 10.1128/aac.35.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Heifetz C. L. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245–258. doi: 10.1016/0732-8893(91)90039-i. [DOI] [PubMed] [Google Scholar]
  6. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Khardori N., Elting L., Wong E., Schable B., Bodey G. P. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis. 1990 Nov-Dec;12(6):997–1003. doi: 10.1093/clinids/12.6.997. [DOI] [PubMed] [Google Scholar]
  8. Khardori N., Reuben A., Rosenbaum B., Rolston K., Bodey G. P. In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents. Antimicrob Agents Chemother. 1990 Aug;34(8):1609–1610. doi: 10.1128/aac.34.8.1609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lecso-Bornet M., Pierre J., Sarkis-Karam D., Lubera S., Bergogne-Berezin E. Susceptibility of Xanthomonas maltophilia to six quinolones and study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob Agents Chemother. 1992 Mar;36(3):669–671. doi: 10.1128/aac.36.3.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Louie A., Baltch A. L., Ritz W. J., Smith R. P. Comparative in-vitro susceptibilities of Pseudomonas aeruginosa, Xanthomonas maltophilia, and Pseudomonas spp. to sparfloxacin (CI-978, AT-4140, PD131501) and reference antimicrobial agents. J Antimicrob Chemother. 1991 Jun;27(6):793–799. doi: 10.1093/jac/27.6.793. [DOI] [PubMed] [Google Scholar]
  11. Zuravleff J. J., Yu V. L. Infections caused by Pseudomonas maltophilia with emphasis on bacteremia: case reports and a review of the literature. Rev Infect Dis. 1982 Nov-Dec;4(6):1236–1246. doi: 10.1093/clinids/4.6.1236. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES